Endocrine and multiple sclerosis outcomes in patients with autoimmune thyroid events in the alemtuzumab CARE-MS studies

Jahr

2023

Autoren

Dayan CM, Lecumberri B, Muller I, Ganesananthan S, Hunter SF, Selmaj KW, Hartung HP, Havrdova EK, LaGanke CC, Ziemssen T, Van Wijmeersch B, Meuth SG, Margolin DH, Poole EM, Baker DP, Senior PA.

Verlag

Mult Scler J Exp Transl Clin. 2023 Jan 3;9(1):20552173221142741.

Link

https://doi.org/10.1177/20552173221142741

Endocrine and multiple sclerosis outcomes in patients with autoimmune thyroid events in the alemtuzumab CARE-MS studies

Beyond B Cell Depletion: Adhesion and Activation Network Remodeling During Repeated Intravenous Anti-CD20 Therapy in Multiple Sclerosis

Jump assessment on a force plate—an approach to quantify subtle lower limb neuromuscular deficits in people with multiple sclerosis

Adherence to risk minimization measures for alemtuzumab use in multiple sclerosis: a drug utilization study in four European countries

Patient profiling in relapsing multiple sclerosis: insights from a real-world observational study into the unmet medical needs of patients on disease-modifying therapy

Immersive Virtual Reality Assessment in Multiple Sclerosis: Patient-Reported Experience and Correlates